Search Clinical Trials
Parent Therapeutic Areas: Oncology | Dermatology/Plastic Surgery

Malignant Melanoma

California

Laverne : Research Site

A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Los Angeles : Research Site:

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Los Angeles : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

San Diego : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

San Francisco : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Santa Monica : Research Site

A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Santa Monica : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Vallejo : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Colorado

Denver : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Denver : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Florida

Miami : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Orlando : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Tampa : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Illinois

Chicago : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Indiana

Indianapolis : Research Site

A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Kentucky

Hazard : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Maryland

Baltimore : Research Site

A Randomized, Double-Blind, Multi-Center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Massachusetts

Boston : Research Site:

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Boston : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Minnesota

Rochester : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Missouri

Columbia : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

St. Louis : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Nevada

Las Vegas : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

New Mexico

Albuquerque : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

New York

New York : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

New York : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Rochester : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Oregon

Portland : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Pennsylvania

Philadelphia : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Pittsburgh : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Pittsburgh : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Rhode Island

Providence : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Tennessee

Memphis : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Nashville : Research Site:

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Nashville : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Texas

Dallas : Research Site:

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Dallas : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Houston : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplatons A10 And AS2-1 In Patients With Malignant Melenoma

Virginia

Charlottesville : University of Virginia

Evaluation of the Effects of Local GM-CSF-in-adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes ( HIC # 8380)

Charlottesville : University of Virginia

Phase II Trial for the Evaluation of the Efficacy of Vaccination with Synthetic Melanoma Peptides Administered with GM-CSF-in-adjuvant in Patients with Advanced Melanoma HIC #10049

Washington

Seattle : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Australia

Melbourne : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Newcastle : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Sydney : Research Site:

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Austria

Wien : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Canada

Calgary, AB : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Edmonton, AB : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Montreal, QC : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

France

Bordeaux : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Marseille : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Nantes : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Germany

Kiel : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Mannheim : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Tübingen : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Italy

Firenze : Research Site:

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.

Genova : Research Site:

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.

Milano : Research Site:

A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.

Milano : Research Site:

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.

Milano : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Siena : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Netherlands

Rotterdam : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Russian Federation

Rayazan : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Voronezh : Local Institution

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Spain

Madrid : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Valencia : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Switzerland

Zürich : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

United Kingdom

Glasgow : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma

Northwood : Research Site:

A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma